trending Market Intelligence /marketintelligence/en/news-insights/trending/l_yQGASw7H0qK-eZEnAepg2 content esgSubNav
In This List

Galmed Pharmaceuticals chairman resigns; CEO named as replacement


Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection


Japan M&A By the Numbers: Q4 2023


Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Galmed Pharmaceuticals chairman resigns; CEO named as replacement

Galmed Pharmaceuticals Ltd. said Chairman Chaim Hurwitz resigned on Dec. 25 to pursue other opportunities, effective immediately.

The Tel Aviv, Israel-based company said CEO and board member Allen Baharaff will replace Hurwitz, subject to shareholder approval.

Hurwitz joined the board in 2011 and has been a member of the audit, nominating and tech committees.

Baharaff, who co-founded the company in 2000, was named CEO in 2012 and president in 2015.

Galmed also appointed board member David Sidransky as chair of the nominating committee and lead independent director, a newly created role that serves as a liaison between the chairman and the independent directors.

Galmed develops therapeutics to treat liver diseases.